hepatocellular carcinoma
Conditions
Interventions
Perioperative Treatment group:neoadjuvant therapy (tirellizumab combined with lenvatinib, 3 cycles), liver section, postoperative adjuvant therapy (tirellizumab combined with lenvatinib, 6 cycles)
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 years and 75 years; 2. Hepatocellular carcinoma diagnosed by pathological examination; 3. CNLC Stage Ib-IIIa; 4. Surgical assessment is resectable: residual liver volume more than 40% for patients with liver cirrhosis and more than 30% for patients without liver cirrhosis; 5. Child-Pugh =7 points; 6. ECOG PS 0-1; 7. Laboratory test results should meet: (1) absolute neutrophil count =2.0×10^9/L; hemoglobin =85g/L; platelet count =75×10^9/L; (2) serum albumin =30g/L; total bilirubin 2000IU/mL requires antiviral treatment for 2 weeks. 8. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Received any anti-tumor therapy in the past; 2. In combined with severe heart, lung, kidney or other important organ dysfunction, unable to tolerate general anesthesia surgery; 3. With main portal vein cancer thrombus; 4. History of severe allergic reactions to other monoclonal antibodies; 5. Other malignant tumors were combined within 2 years; 6. With immune deficiency or autoimmune disease; 7. HIV infection; 8. Other investigators believe that it may be risky to receive the study treatment or not suitable for inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathological response rate;Disease-free survival;Event-free survival;overall survival;Pathological complete response rate;Rate of microvascular invasion;Incidence of adverse events;Incidence of postoperative complications; | — |
Countries
China
Contacts
Public ContactKun Wang
Beijing Cancer Hospital
Outcome results
None listed